BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Transplant. Jun 18, 2026; 16(2): 118012
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118012
Table 6 Currently approved respiratory syncytial virus vaccines in chronic liver disease patients/Liver transplantation recipients
Vaccine (brand)
Recommended adult use
Clinical notes in CLD /LT
RSVpreF (Abrysvo®, Pfizer), RSVpreF3 OA (Arexvy®, GSK), mRNA-1345 (mRESVIA®, Moderna)A single i.m. dose in adults with CLD aged 60-74 years prior to RSV season; a single intramuscular dose to adults undergoing LT at least 2 weeks prior to LT, or at least 6 months afterwardsNo recommendations on booster dosing are yet available


Write to the Help Desk